Risk-adjusted female breast cancer incidence rates in the United States
- PMID: 21903503
- DOI: 10.1016/j.canep.2011.08.004
Risk-adjusted female breast cancer incidence rates in the United States
Abstract
A method has been previously proposed for estimating risk-adjusted incidence rates (RAIRs) from cancer data from the Surveillance, Epidemiology, and End Results (SEER) program. Unlike conventionally reported SEER-based cancer incidence rates in the United States, but similar to the approach taken by the International Association of Cancer Registries and the International Agency for Research on Cancer, the method uses only the first primary cancer of the given site. In addition, it also adjusts for population-based cancer prevalence in order to obtain a better population-based measure of cancer risk. For most cancers multiple cancer primaries are rare and the prevalence of the disease is low. However, female breast cancer has a comparatively high risk of subsequent breast cancers and is the most prevalent cancer in women. Hence, in white women RAIRs are 3.0% lower in ages 30-39, 4.2% lower in ages 40-49, 4.0% lower in ages 50-59, 4.1% lower in ages 60-69, 3.8% lower in ages 70-79, and 4.3% lower in ages 80 years and older compared with conventional rates. Corresponding lower percentages for black women are 3.9%, 6.9%, 5.1%, 7.8%, 6.0%, and 2.2%, respectively. Age-group specific trends in breast cancer incidence rates differed between RAIRs and conventional incidence rates, increasingly so with older age. The number of cancer cases in the United States is estimated from conventional incidence rates and population estimates. In 2007, the estimated number of malignant breast cancer cases was 181,665 for white women and 20,203 for black women. The estimated number of breast cancer cases decreased by 4.8% for whites and 6.5% for blacks when based on RAIRs. RAIRs are a better measure of breast cancer risk and trends in RAIRs are better for monitoring the effect of risk factors.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment.J Natl Cancer Inst. 2005 Oct 5;97(19):1407-27. doi: 10.1093/jnci/dji289. J Natl Cancer Inst. 2005. PMID: 16204691
-
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.Oncologist. 1996;1(5):326-330. Oncologist. 1996. PMID: 10388011
-
Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome.Breast Cancer Res Treat. 2005 Mar;90(2):127-37. doi: 10.1007/s10549-004-3777-3. Breast Cancer Res Treat. 2005. PMID: 15803359
-
Epidemiology of breast cancer in young women.Breast Dis. 2005-2006;23:3-8. doi: 10.3233/bd-2006-23102. Breast Dis. 2005. PMID: 16823161 Review.
-
Breast Cancer Epidemiology in Gulf Cooperation Council Countries: A Regional and International Comparison.Clin Breast Cancer. 2018 Jun;18(3):e381-e392. doi: 10.1016/j.clbc.2017.07.006. Epub 2017 Jul 13. Clin Breast Cancer. 2018. PMID: 28781021 Review.
Cited by
-
Results of an online community needs assessment for psychoeducational interventions among partners of hereditary breast cancer previvors and survivors.J Med Internet Res. 2012 Jan 18;14(1):e15. doi: 10.2196/jmir.1847. J Med Internet Res. 2012. PMID: 22257650 Free PMC article.
-
Multiscale computational evaluation of Vitex trifolia phytochemicals as VEGFR2 inhibitors for targeted breast cancer therapy.PLoS One. 2025 Jun 10;20(6):e0325255. doi: 10.1371/journal.pone.0325255. eCollection 2025. PLoS One. 2025. PMID: 40493694 Free PMC article.
-
Adenosine arrests breast cancer cell motility by A3 receptor stimulation.Purinergic Signal. 2016 Dec;12(4):673-685. doi: 10.1007/s11302-016-9531-6. Epub 2016 Aug 30. Purinergic Signal. 2016. PMID: 27577957 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical